Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises BWB Partners in the sale of Heatex AB to the American industrial group Madison Industries
Mandate

Vinge advises BWB Partners in the sale of Heatex AB to the American industrial group Madison Industries

December 18, 2020 M&A

Vinge advises BWB Partners and the company’s minority shareholders in the sale of Heatex AB to the American industrial group Madison Industries.

Heatex is a global manufacturer of air-to-air heat exchangers for applications in various buildings, data centers as well as wind turbines. Heatex is headquartered in Malmö with 169 employees in Europe, US and China. In 2020, Heatex is expected to generate revenue of approx. SEK 360 million.

The Vinge team consisted primarily of Jesper Ottergren and Henrik Borna.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024